Company news

Edgewise Therapeutics, Inc. news in 2023

Edgewise Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

December 18, 2023

Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community

December 17, 2023

Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

November 29, 2023

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 8, 2023

Edgewise Therapeutics to Present at Upcoming Investor Conferences

November 7, 2023

Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023

October 31, 2023

Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)

October 25, 2023

Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society

September 26, 2023

Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

September 25, 2023

Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction

September 13, 2023

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 9, 2023

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

June 25, 2023

Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference

June 5, 2023

Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023

Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

March 29, 2023

Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

March 20, 2023

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

March 13, 2023

Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

March 5, 2023

Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023

February 28, 2023

Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology

February 27, 2023

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 22, 2023

Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

February 6, 2023

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 3, 2023

Decks in 2023